Merck & Co., Inc. MRK
148.78
0.80
0.54%
as of 25 Sep
- Market cap
- $365.4B
- P/E
- 119×
Follow MRK
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Merck & Co., Inc. (MRK) Shares outstanding
Merck & Co., Inc.'s shares outstanding at the end of fiscal 2025 was $2.5B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $2.5B. Over the past ten years it has ranged from $2.5B (fiscal 2025) to $2.8B (fiscal 2015) — the current reading is the lowest in ten years. Merck & Co., Inc. ranks 3rd of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Annual
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $2.5B | (1.34%) |
| FY2024 | $2.5B | (0.24%) |
| FY2023 | $2.5B | 0.20% |
| FY2022 | $2.5B | 0.16% |
| FY2021 | $2.5B | (0.12%) |
| FY2020 | $2.5B | (1.51%) |
| FY2019 | $2.6B | (3.70%) |
| FY2018 | $2.7B | (2.51%) |
| FY2017 | $2.7B | (1.40%) |
| FY2016 | $2.8B | (1.90%) |
Quarterly
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $2.5B | (0.08%) |
| Mar 2026 | $2.5B | (1.40%) |
| Dec 2025 | $2.5B | 0.36% |
| Sep 2025 | $2.5B | (0.60%) |
| 42 more quarters | Free account |
Against its own ten years
Low $2.5B
High $2.8B
Ten-year median
$2.5B
Current reading's percentile
9
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.7B |
| NVO Novo Nordisk A/S compare | $4.4B |
| MRK Merck & Co., Inc. | $2.5B |
| JNJ Johnson & Johnson compare | $2.4B |
| NVS Novartis AG compare | $1.9B |
| ABBV AbbVie Inc. compare | $1.8B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. compare | $1.2B |
| AMGN Amgen Inc. compare | $544.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on MRK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- The full statement